Hernández DS, Gómez CMJ

Language: Spanish
References: 18
Page: 154-159
PDF size: 269.55 Kb.

ABSTRACT

Introduction: Alzheimer's disease (AD) is defined as a neurodegenerative disorder characterized by the accumulation of beta-amyloid plaques in the brain, resulting in histopathological alterations, manifesting mainly as cognitive dysfunction (CD). Objective: to assess the efficacy of Lecanemab on CD in patients with AD. Material and methods: a meta-analysis of original research articles evaluating CD during intervention periods with placebo and lecanemab was conducted. Results: the global sample comprised 5,069 subjects. The intervention duration was 12 and 18 months, with 10 mg/kg of lecanemab administered biweekly. Conclusion: a dose of 10 mg/kg significantly reduced CD in patients with AD, with more favorable outcomes observed at 18 months compared to 12 months of treatment.

REFERENCES

1. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023; 19 (4): 1598-1695. doi: 10.1002/alz.13016.

2. Janeiro MH, Ardanaz CG, Sola-Sevilla N, Dong J, Cortés-Erice M, Solas M et al. Biomarkers in Alzheimer's disease. Adv Lab Med. 2020; 2 (1): 27-50. doi: 10.1515/almed-2020-0090.

3. Beata BK, Wojciech J, Johannes K, Piotr L, Barbara M. Alzheimer's disease-biochemical and psychological background for diagnosis and treatment. Int J Mol Sci. 2023; 24 (2): 1059. doi: 10.3390/ijms24021059.

4. Guía de Práctica Clínica: Diagnóstico y tratamiento de la enfermedad de Alzheimer [Internet]. México: Instituto Mexicano del Seguro Social; 2012. Disponible en: https://www.imss.gob.mx/sites/all/statics/guiasclinicas/144GRR.pdf

5. McDade E, Cummings JL, Dhadda S, Swanson CJ, Reyderman L, Kanekiyo M et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022; 14 (1): 191. doi: 10.1186/s13195-022-01124-2.

6. Custodio N, Becerra-Becerra Y, Alva-Diaz C, Montesinos R, Lira D, Herrera-Pérez E et al. Validación y precisión de la escala de deterioro global (GDS) para establecer severidad de demencia en una población de Lima. CES Med. 2017; 31 (1): 14-26. doi: 10.21615/cesmedicina.31.1.2.

7. Rostagno AA. Pathogenesis of Alzheimer's disease. Int J Mol Sci. 2022; 24 (1): 107. doi: 10.3390/ijms24010107.

8. von Bernhardi MR. Mecanismos neurobiológicos de la enfermedad de Alzheimer. Rev Chil Neuro-Psiquiatr. 2005; 43 (2): 123-132. doi: 10.4067/s0717-92272005000200005.

9. Guzman-Martinez L, Calfío C, Farias GA, Vilches C, Prieto R, Maccioni RB. New frontiers in the prevention, diagnosis, and treatment of Alzheimer's disease. J Alzheimers Dis. 2021; 82 (s1): S51-S63. doi: 10.3233/JAD-201059.

10. López Locanto O. Tratamiento farmacológico de la enfermedad de Alzheimer y otras demencias. Arch Med Int. 2015; 37 (2): 61-67.

11. (Leqemb^iTM) en enfermedad de Alzheimer / Lecanemab (Leqembi^TM) in Alzheimer's disease. [s/f].

12. van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023; 388 (1): 9-21. doi: 10.1056/NEJMoa2212948.

13. Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody. Alzheimers Res Ther. 2021; 13 (1): 80. doi: 10.1186/s13195-021-00813-8.

14. Berry DA, Dhadda S, Kanekiyo M, Li D, Swanson CJ, Irizarry M et al. Lecanemab for patients with early Alzheimer disease: Bayesian analysis of a phase 2b dose-finding randomized clinical trial. JAMA Netw Open. 2023; 6 (4): e237230. doi: 10.1001/jamanetworkopen.2023.7230.

15. Cohen S, van Dyck CH, Gee M, Doherty T, Kanekiyo M, Dhadda S et al. Lecanemab clarity AD: quality-of-life results from a randomized, double-blind phase 3 trial in early Alzheimer's disease. J Prev Alzheimers Dis. 2023; 10 (4): 771-777. doi: 10.14283/jpad.2023.123.

16. Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease. Adv Clin Exp Med. 2023; 32 (9): 943-947. doi: 10.17219/acem/171379.

17. Tahami Monfared AA, Tafazzoli A, Ye W, Chavan A, Zhang Q. Long-term health outcomes of lecanemab in patients with early Alzheimer's disease using simulation modeling. Neurol Ther. 2022; 11 (2): 863-880. doi: 10.1007/s40120-022-00350-y.

18. Varadharajan A, Davis AD, Ghosh A, Jagtap T, Xavier A, Menon AJ et al. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs. J Neurosci Rural Pract. 2023; 14 (4): 566-573. doi: 10.25259/JNRP_356_2023.